Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Translating the biology of aging into novel therapeutics for Alzheimer disease.

Hara Y, McKeehan N, Fillit HM.

Neurology. 2019 Jan 8;92(2):84-93. doi: 10.1212/WNL.0000000000006745. Epub 2018 Dec 7. Review.

2.

Evaluation of the Neuroprotective Potential of N-Acetylcysteine for Prevention and Treatment of Cognitive Aging and Dementia.

Hara Y, McKeehan N, Dacks PA, Fillit HM.

J Prev Alzheimers Dis. 2017;4(3):201-206. doi: 10.14283/jpad.2017.22. Review.

PMID:
29182711
3.

Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease.

Lin PJ, Zhong Y, Fillit HM, Cohen JT, Neumann PJ.

Alzheimers Dement. 2017 Oct;13(10):1174-1178. doi: 10.1016/j.jalz.2017.08.010. Epub 2017 Sep 5.

PMID:
28886338
4.

A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline.

Dacks PA, Armstrong JJ, Brannan SK, Carman AJ, Green AM, Kirkman MS, Krakoff LR, Kuller LH, Launer LJ, Lovestone S, Merikle E, Neumann PJ, Rockwood K, Shineman DW, Stefanacci RG, Velentgas P, Viswanathan A, Whitmer RA, Williamson JD, Fillit HM.

Alzheimers Res Ther. 2016 Aug 20;8:33. doi: 10.1186/s13195-016-0200-3. Review.

5.

Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis.

Lin PJ, Zhong Y, Fillit HM, Chen E, Neumann PJ.

J Am Geriatr Soc. 2016 Aug;64(8):1549-57. doi: 10.1111/jgs.14227. Epub 2016 Jun 13.

PMID:
27295430
6.

Recognizing the Spectrum of Cognitive Impairment to Advance Drug Discovery.

Dacks PA, Fillit HM.

J Am Med Dir Assoc. 2016 May 1;17(5):457-8. doi: 10.1016/j.jamda.2016.02.022. Epub 2016 Mar 9. No abstract available.

PMID:
26969533
7.

Expert consensus document: Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions.

Carman AJ, Ferguson R, Cantu R, Comstock RD, Dacks PA, DeKosky ST, Gandy S, Gilbert J, Gilliland C, Gioia G, Giza C, Greicius M, Hainline B, Hayes RL, Hendrix J, Jordan B, Kovach J, Lane RF, Mannix R, Murray T, Seifert T, Shineman DW, Warren E, Wilde E, Willard H, Fillit HM.

Nat Rev Neurol. 2015 Apr;11(4):230-44. doi: 10.1038/nrneurol.2015.30. Epub 2015 Mar 17. Review.

PMID:
25776822
8.

Overcoming obstacles to repurposing for neurodegenerative disease.

Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, Fillit HM.

Ann Clin Transl Neurol. 2014 Jul;1(7):512-8. doi: 10.1002/acn3.76. Epub 2014 Jun 24.

9.

Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease.

Lin PJ, Yang Z, Fillit HM, Cohen JT, Neumann PJ.

Health Aff (Millwood). 2014 Apr;33(4):547-54. doi: 10.1377/hlthaff.2013.1276.

PMID:
24711313
10.

Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.

Carman AJ, Dacks PA, Lane RF, Shineman DW, Fillit HM.

J Nutr Health Aging. 2014 Apr;18(4):383-92. doi: 10.1007/s12603-014-0021-7. Review.

PMID:
24676319
11.

Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making.

Dacks PA, Andrieu S, Blacker D, Carman AJ, Green AM, Grodstein F, Henderson VW, James BD, Lane RF, Lau J, Lin PJ, Reeves BC, Shah RC, Vellas B, Yaffe K, Yurko-Mauro K, Shineman DW, Bennett DA, Fillit HM.

J Prev Alzheimers Dis. 2014 Feb;1(2):117-123.

12.

Developing novel blood-based biomarkers for Alzheimer's disease.

Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, Mielke MM, O'Bryant S, Sarasa M, Sjøgren M, Soares H, Teeling J, Trushina E, Ward M, West T, Bain LJ, Shineman DW, Weiner M, Fillit HM.

Alzheimers Dement. 2014 Jan;10(1):109-14. doi: 10.1016/j.jalz.2013.10.007. Review.

13.

Evidence needs to be translated, whether or not it is complete.

Dacks PA, Bennett DA, Fillit HM.

JAMA Neurol. 2014 Feb;71(2):137-8. doi: 10.1001/jamaneurol.2013.5376. Review. No abstract available.

PMID:
24297103
14.

Progress in novel cognitive enhancers for cognitive aging and Alzheimer's disease.

Shineman DW, Carman AJ, Dacks PA, Lane RF, Fillit HM.

Alzheimers Res Ther. 2013 Oct 2;5(5):45. doi: 10.1186/alzrt209. eCollection 2013.

15.

Optimizing the use of CROs by academia and small companies.

Lane RF, Friedman LG, Keith C, Braithwaite SP, Frearson JA, Lowe DA, Longo FM, Refolo LM, Watterson DM, Tsaioun K, Shineman DW, Fillit HM.

Nat Rev Drug Discov. 2013 Jul;12(7):487-8. doi: 10.1038/nrd4057. No abstract available.

PMID:
23812255
16.

Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease.

Dacks PA, Shineman DW, Fillit HM.

J Nutr Health Aging. 2013 Mar;17(3):240-51. doi: 10.1007/s12603-012-0431-3.

PMID:
23459977
17.
18.

Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders.

Lin PJ, Fillit HM, Cohen JT, Neumann PJ.

Alzheimers Dement. 2013 Jan;9(1):30-8. doi: 10.1016/j.jalz.2012.11.002.

PMID:
23305822
19.

Beyond amyloid: the future of therapeutics for Alzheimer's disease.

Lane RF, Shineman DW, Steele JW, Lee LB, Fillit HM.

Adv Pharmacol. 2012;64:213-71. doi: 10.1016/B978-0-12-394816-8.00007-6. Review.

PMID:
22840749
20.

Clinical trials: new opportunities.

Chapman SB, Cotman CW, Fillit HM, Gallagher M, van Dyck CH.

J Gerontol A Biol Sci Med Sci. 2012 Jun;67(7):773-80. doi: 10.1093/gerona/gls126. Epub 2012 May 8. Review.

21.

Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias.

Lane RF, Shineman DW, Fillit HM.

Alzheimers Res Ther. 2011 Dec 15;3(6):36. doi: 10.1186/alzrt99.

22.

Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies.

Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjänheikki J, Fillit HM.

Alzheimers Res Ther. 2011 Sep 28;3(5):28. doi: 10.1186/alzrt90.

23.

An analysis of global research funding for the frontotemporal dementias: 1998-2008.

Walentas CD, Shineman DW, Horton AR, Boeve BF, Fillit HM.

Alzheimers Dement. 2011 Mar;7(2):142-50. doi: 10.1016/j.jalz.2010.11.010. Epub 2011 Jan 26.

PMID:
21276758
25.

Therapeutics for cognitive aging.

Shineman DW, Salthouse TA, Launer LJ, Hof PR, Bartzokis G, Kleiman R, Luine V, Buccafusco JJ, Small GW, Aisen PS, Lowe DA, Fillit HM.

Ann N Y Acad Sci. 2010 Apr;1191 Suppl 1:E1-15. doi: 10.1111/j.1749-6632.2010.05532.x.

26.

Alzheimer's disease drug discovery: Abeta and beyond.

Shineman DW, Fillit HM.

Curr Alzheimer Res. 2010 May;7(3):188-9. No abstract available.

PMID:
20406195
27.

A multi-targeted approach for a complex multifaceted disease.

Shineman DW, Fillit HM.

Curr Alzheimer Res. 2009 Oct;6(5):407-8. No abstract available.

PMID:
19860641
28.

Novel strategies for the prevention of dementia from Alzheimer's disease.

Shineman DW, Fillit HM.

Dialogues Clin Neurosci. 2009;11(2):129-34. Review.

29.

Meeting the unique challenges of drug discovery for neurodegenerative diseases.

Shineman DW, Fillit HM.

BMC Neurol. 2009 Jun 12;9 Suppl 1:I1. doi: 10.1186/1471-2377-9-S1-I1. No abstract available.

30.

Practicality of a computerized system for cognitive assessment in the elderly.

Fillit HM, Simon ES, Doniger GM, Cummings JL.

Alzheimers Dement. 2008 Jan;4(1):14-21. doi: 10.1016/j.jalz.2007.09.008.

PMID:
18631946
31.

Drug discovery for Alzheimer's disease: filling the pipeline.

Horton AR, Fillit HM.

Curr Alzheimer Res. 2007 Dec;4(5):501-2. No abstract available.

PMID:
18220510
32.

Recommendations for best practices in the treatment of Alzheimer's disease in managed care.

Fillit HM, Doody RS, Binaso K, Crooks GM, Ferris SH, Farlow MR, Leifer B, Mills C, Minkoff N, Orland B, Reichman WE, Salloway S.

Am J Geriatr Pharmacother. 2006;4 Suppl A:S9-S24; quiz S25-S28.

PMID:
17157793
33.

Partnerships between philanthropy, government and industry are needed to advance drug discovery for neurodegenerative diseases.

Refolo LM, Fillit HM.

Curr Alzheimer Res. 2006 Jul;3(3):175-6. No abstract available.

PMID:
16842090
34.

Advancing drug discovery for Alzheimer's disease.

Fillit HM, Refolo LM.

Curr Alzheimer Res. 2005 Apr;2(2):105-7. No abstract available.

PMID:
15974904
35.

New directions in neuroprotection: basic mechanisms, molecular targets and treatment strategies.

Refolo LM, Fillit HM.

J Alzheimers Dis. 2004 Dec;6(6 Suppl):S1-2. No abstract available.

PMID:
15665407
36.

Drug discovery for Alzheimer's disease: the end of the beginning.

Refolo LM, Fillit HM.

J Mol Neurosci. 2004;24(1):1-8. No abstract available.

PMID:
15314243
37.

Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.

Refolo LM, Fillit HM.

J Mol Neurosci. 2004;23(3):151-5. Review.

PMID:
15181243
38.

Autoimmune markers in HIV-associated dementia.

Schutzer SE, Brunner M, Fillit HM, Berger JR.

J Neuroimmunol. 2003 May;138(1-2):156-61.

PMID:
12742665
39.

Tau and Alzheimer's disease: the long road to anti-tangle therapeutics.

Fillit HM, Refolo LM.

J Mol Neurosci. 2002 Dec;19(3):249-50. No abstract available.

PMID:
12540049
40.

The role of hormone replacement therapy in the prevention of Alzheimer disease.

Fillit HM.

Arch Intern Med. 2002 Sep 23;162(17):1934-42. Review.

PMID:
12230415
41.

Strategies for drug discovery for cognitive aging and Alzheimer's disease.

Fillit HM, O'Connell AW, Refolo LM.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):1-3. No abstract available.

PMID:
12212763
42.

Achieving and maintaining cognitive vitality with aging.

Fillit HM, Butler RN, O'Connell AW, Albert MS, Birren JE, Cotman CW, Greenough WT, Gold PE, Kramer AF, Kuller LH, Perls TT, Sahagan BG, Tully T.

Mayo Clin Proc. 2002 Jul;77(7):681-96. Review.

PMID:
12108606
43.

Barriers to drug discovery and development for Alzheimer disease.

Fillit HM, O'Connell AW, Brown WM, Altstiel LD, Anand R, Collins K, Ferris SH, Khachaturian ZS, Kinoshita J, Van Eldik L, Dewey CF.

Alzheimer Dis Assoc Disord. 2002;16 Suppl 1:S1-8. Review.

PMID:
12070355
44.

Public attitudes about genetic testing for Alzheimer's disease.

Neumann PJ, Hammitt JK, Mueller C, Fillit HM, Hill J, Tetteh NA, Kosik KS.

Health Aff (Millwood). 2001 Sep-Oct;20(5):252-64.

PMID:
11558711
45.

Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.

Rice DP, Fillit HM, Max W, Knopman DS, Lloyd JR, Duttagupta S.

Am J Manag Care. 2001 Aug;7(8):809-18. Review.

46.

Managed care decisions in Alzheimer's disease.

Fillit HM.

Am J Manag Care. 2000 Dec;6(22 Suppl):S1149-55; discussion S1156-60. Review.

47.

The pharmacoeconomics of Alzheimer's disease.

Fillit HM.

Am J Manag Care. 2000 Dec;6(22 Suppl):S1139-44; discussion S1145-8. Review.

48.

Impact of donepezil on caregiving burden for patients with Alzheimer's disease.

Fillit HM, Gutterman EM, Brooks RL.

Int Psychogeriatr. 2000 Sep;12(3):389-401.

PMID:
11081959
49.

Specificities of heparin-binding sites from the amino-terminus and type 1 repeats of thrombospondin-1.

Yu H, Tyrrell D, Cashel J, Guo NH, Vogel T, Sipes JM, Lam L, Fillit HM, Hartman J, Mendelovitz S, Panel A, Roberts DD.

Arch Biochem Biophys. 2000 Feb 1;374(1):13-23.

PMID:
10640391
50.

Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews.

Fillit HM, Futterman R, Orland BI, Chim T, Susnow L, Picariello GP, Scheye EC, Spoeri RK, Roglieri JL, Warburton SW.

Am J Manag Care. 1999 May;5(5):587-94.

Supplemental Content

Loading ...
Support Center